Home / Health / Ebola's Deadly Bundibugyo Strain Lacks Approved Treatments
Ebola's Deadly Bundibugyo Strain Lacks Approved Treatments
4 Nov
Summary
- Bundibugyo Ebola strain has no approved medical interventions.
- 782 cases and 181 deaths confirmed in eastern DRC.
- Experimental vaccines and therapies are under urgent evaluation.
The Democratic Republic of Congo is facing an urgent global health challenge with an outbreak of the Bundibugyo strain of Ebola in its eastern region. This specific strain, unlike the more common Zaire strain, currently has no approved medical interventions, posing a significant threat with a fatality rate potentially as high as 40 percent. As of recently, the Congolese Ministry of Health reported 782 confirmed cases and 181 confirmed deaths.
Global health organizations are rapidly evaluating a range of experimental solutions. These include promising vaccine candidates like a single-dose rVSV Bundibugyo vaccine from the International AIDS Vaccine Initiative and Oxford University's ChAdOx1 Bundibugyo vaccine. Additionally, antibody drugs such as Mapp Biopharmaceutical's MBP134 and Regeneron Pharmaceuticals' maftivimab are being explored.
Antiviral drugs like Gilead Sciences' obeldesivir are also under consideration for post-exposure treatment. The World Health Organization (WHO) is prioritizing several of these experimental options, while also investigating if existing Ebola treatments could offer protection, though current evidence is limited to animal studies. The development and testing of these potential interventions are progressing with the goal of rapid deployment.
